InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,107.19
(
0.99%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.41
(
0.42%
)
Bitcoin
57,594.91
(
-0.28%
)
Post# of 10804
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

stock_peeker

Send PM Follow Ignore
Followers 55
Posts 6022
Boards Moderated 0
Alias Born 01/10/2004

stock_peeker

Re: stock_peeker post# 5886

Thursday, 02/23/2012 10:06:15 AM

Thursday, February 23, 2012 10:06:15 AM

Post# of 10804
09:09 VVUS Vivus upgraded to Mkt Outperform at Rodman & Renshaw; tgt $39
Rodman & Renshaw upgrades VVUS to Mkt Outperform from Mkt Perform and sets target price at $39 following the nearly unanimous panel vote. The firm says VVUS provided a much more cogent and focused risk/benefit proposition compared to that of the July 2010 panel. As well, they found the FDA body language by the medical review staff to be critical to assuaging the majority of the panel members' concerns.

Kurt Vonnegut wrote some great books and had a great philosophy of life:


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up